对《寻找促红细胞生成素（ESA）低反应性的潜在预测因素：一项基于人群的研究》的更正
Correction to: In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study.
作者信息
Ingrasciotta Ylenia, Lacava Viviana, Marcianò Ilaria, Giorgianni Francesco, Tripepi Giovanni, Arrigo Graziella D', Chinellato Alessandro, Tari Daniele Ugo, Santoro Domenico, Trifirò Gianluca
机构信息
Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Via Consolare Valeria 1, Messina, Italy.
Dialysis and Nephrology Unit, University of Messina, Messina, Italy.
出版信息
BMC Nephrol. 2020 Jul 9;21(1):262. doi: 10.1186/s12882-020-01891-w.
Abstract
An amendment to this paper has been published and can be accessed via the original article.
摘要
本文的一篇修正已发表，可通过原始文章获取。
相似文献
1
Correction to: In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study.对《寻找促红细胞生成素（ESA）低反应性的潜在预测因素：一项基于人群的研究》的更正
BMC Nephrol. 2020 Jul 9;21(1):262. doi: 10.1186/s12882-020-01891-w.
2
Minor Elevation in C-Reactive Protein Levels Predicts Incidence of Erythropoiesis-Stimulating Agent Hyporesponsiveness among Hemodialysis Patients.C反应蛋白水平轻度升高可预测血液透析患者中促红细胞生成素低反应性的发生率。
Nephron. 2015;131(2):123-30. doi: 10.1159/000438870. Epub 2015 Sep 8.
3
Improving Erythropoiesis Stimulating Agent Hyporesponsiveness in Hemodialysis Patients: The Role of Hepcidin and Hemodiafiltration Online.提高血液透析患者促红细胞生成素反应性：肝素结合蛋白和在线血液透析滤过的作用。
Blood Purif. 2018;45(1-3):139-146. doi: 10.1159/000485314. Epub 2018 Jan 16.
4
Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia.澳大利亚北部顶端地区原住民维持性血液透析患者的炎症、高铁蛋白及促红细胞生成素抵抗
Hemodial Int. 2014 Oct;18(4):740-50. doi: 10.1111/hdi.12173. Epub 2014 Apr 27.
5
Erythropoiesis-stimulating agent hyporesponsiveness in end-stage renal disease patients.终末期肾病患者对促红细胞生成素的低反应性
Contrib Nephrol. 2015;185:76-86. doi: 10.1159/000380972. Epub 2015 May 19.
6
Importance of Physiological Erythropoiesis in the Treatment of Chronic Kidney Disease-Associated Anemia.生理性红细胞生成在慢性肾脏病相关性贫血治疗中的重要性。
Contrib Nephrol. 2018;196:52-57. doi: 10.1159/000485697. Epub 2018 Jul 24.
7
Management of anaemia: a critical and systematic review of the cost effectiveness of erythropoiesis-stimulating agents.贫血的管理：促红细胞生成素刺激剂成本效益的关键系统性综述
Pharmacoeconomics. 2008;26(2):99-120. doi: 10.2165/00019053-200826020-00002.
8
Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.促红细胞生成素刺激剂治疗化疗所致贫血患者的剂量效率：一项系统评价
Clin Ther. 2014 Apr 1;36(4):594-610. doi: 10.1016/j.clinthera.2014.02.007. Epub 2014 Mar 18.
9
Tumor progression associated with erythropoiesis-stimulating agents.与促红细胞生成素相关的肿瘤进展。
Ann Pharmacother. 2008 Dec;42(12):1865-70. doi: 10.1345/aph.1L231. Epub 2008 Nov 18.
10
Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study.生物类似药、参比产品及其他仍受专利保护的促红细胞生成素（ESA）在慢性肾病和癌症患者中的疗效比较：一项基于意大利人群的研究
PLoS One. 2016 May 17;11(5):e0155805. doi: 10.1371/journal.pone.0155805. eCollection 2016.
本文引用的文献
1
In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study.探寻红细胞生成刺激剂（ESA）低反应性的潜在预测因子：一项基于人群的研究。
BMC Nephrol. 2019 Sep 14;20(1):359. doi: 10.1186/s12882-019-1554-0.
Zotero 插件